Skip to main content
. 2022 Nov 18;48(12):1751–1759. doi: 10.1007/s00134-022-06919-3

Table 2.

Primary and secondary outcomes

NIV (n = 92) HFNC (n = 90) Difference between groups (95%CI), p
Primary outcome, n (%)
All-cause reintubation 21 (22.8) 35 (38.9) −16.0 (−29.2 to −0.3), p = 0.019
Secondary outcomes
Postextubation respiratory failure, n (%) 40 (43.5) 40 (44.4) −0.9 (−15.4‒13.5), p = 0.896
Ventilator-associated tracheobronchitis, n (%) 0 (0) 1 (1.1) −1.1 (−3.3‒1.1), p = 0.495
Ventilator-associated pneumonia, n (%) 4 (4.3) 7 (7.8) −3.4 (−10.4‒3.5), p = 0.369
Other infections, n (%) 1 (1.1) 2 (2.2) −1.1 (−4.8‒2.6), p = 0.619
Sepsis, n (%) 4 (4.3) 3 (3.3) 1 (−5.5‒7.6), p = 1.000
Multiorgan failure, n (%) 3 (3.3) 2 (2.2) 1 (−4.5‒6.6), p = 1.000
Hospital LOS, median (IQR), d 20 (12‒36.7) 26.5 (15‒45) 6.5 (0.5‒21.1), p = 0.068
ICU LOS, median (IQR), d 9.5 (4‒15) 12.5 (6.7‒19) 3 (−0.6‒5.6), p = 0.047
ICU mortality, n (%) 12 (13) 4 (4.4) 9.7 (−1.1‒18.7), p = 0.356
Hospital mortality, n (%) 14 (15.2) 6 (6.7) 8.5 (−0.7‒18), p = 0.475
Time to reintubation, median (IQR), h 27 (6‒47) 27 (8‒48) 0 (−25‒25), p = 0.582
Intolerance to therapy, n (%) 19 (20.7) 8 (8.9) 11.7 (1.6–21.9), p = 0.026
Nasal discomfort, n (%) 18 (19.6) 6 (6.7) 12.9 (3.3–22.5), p = 0.010
Facial skin ulcer, n (%) 4 (4.3) 0 (0) 4.3 (0.1–8.5), p = 0.045
Exploratory outcomes
Time on therapy 0–24 h, median (IQR), h 22.5 (19.25‒24) 24 (24‒24)  < 0.001
Time on therapy 24‒48 h, median (IQR), h 18 (10.5‒22) 20 (8‒24) 0.060
Temperature, median (IQR), °C 29 (29‒29) 37 (37‒37)  < 0.001
Reintubation rate at 5 d, n (%) 21 (23.3) 26 (28.8) 0.321
Time to reintubation at 5 d, median (IQR), h 27 (6‒47) 10 (6.5‒28) 0.029
FiO2 after 48 h, median (IQR), % 31.3 (9) 31.8 (8) 0.645

HFNC high-flow nasal cannula; ICU intensive care unit; IQR interquartile range; LOS length of stay; NIV noninvasive ventilation